355 related articles for article (PubMed ID: 36874119)
1. Immunotherapy associated central nervous system complications in primary brain tumors.
Mantica M; Drappatz J
Front Oncol; 2023; 13():1124198. PubMed ID: 36874119
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
3. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
Quintarelli C; Camera A; Ciccone R; Alessi I; Del Bufalo F; Carai A; Del Baldo G; Mastronuzzi A; De Angelis B
Front Immunol; 2021; 12():634031. PubMed ID: 34163465
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy.
Song KW; Scott BJ; Lee EQ
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):827-839. PubMed ID: 37938472
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy approaches in the treatment of malignant brain tumors.
Dunn-Pirio AM; Vlahovic G
Cancer; 2017 Mar; 123(5):734-750. PubMed ID: 27875627
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity.
Finch EA; Duke E; Hwang EI; Packer RJ
Pediatr Neurol; 2020 Jun; 107():7-15. PubMed ID: 32113728
[TBL] [Abstract][Full Text] [Related]
7. The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.
Maxwell R; Luksik AS; Garzon-Muvdi T; Lim M
Curr Neurol Neurosci Rep; 2017 Jun; 17(6):50. PubMed ID: 28488122
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
11. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
12. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
14. Neurological complications of cancer immunotherapy.
Roth P; Winklhofer S; Müller AMS; Dummer R; Mair MJ; Gramatzki D; Le Rhun E; Manz MG; Weller M; Preusser M
Cancer Treat Rev; 2021 Jun; 97():102189. PubMed ID: 33872978
[TBL] [Abstract][Full Text] [Related]
15. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
16. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology.
Foster JB; Alonso MM; Sayour E; Davidson TB; Persson ML; Dun MD; Kline C; Mueller S; Vitanza NA; van der Lugt J
Neoplasia; 2023 Aug; 42():100909. PubMed ID: 37244226
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
18. CAR T cells for brain tumors: Lessons learned and road ahead.
Akhavan D; Alizadeh D; Wang D; Weist MR; Shepphird JK; Brown CE
Immunol Rev; 2019 Jul; 290(1):60-84. PubMed ID: 31355493
[TBL] [Abstract][Full Text] [Related]
19. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.
Xue T; Zhao X; Zhao K; Lu Y; Yao J; Ji X
Curr Probl Cancer; 2022 Feb; 46(1):100791. PubMed ID: 34538649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
